CymaBay Therapeutics, Inc. (CBAY) Stock: A Biotechnology Stock That’s Making Its Way For The Bottom


CymaBay Therapeutics, Inc. (CBAY) is headed down in the market today. The stock, one that is focused in the biotechnology space, is currently trading at $11.93 after a move down of -7.66% so far today. In terms of biotechnology companies, there are a number of factors that have the ability to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent stories associated with CBAY:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-12-19 08:00AM CymaBay Therapeutics to Present at Upcoming Investor Conferences in March
Mar-11-19 04:05PM CymaBay Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters Option to Purchase Additional Shares
Mar-06-19 08:00AM CymaBay Announces Pricing of Public Offering of Common Stock
Mar-05-19 08:26PM Edited Transcript of CBAY earnings conference call or presentation 28-Feb-19 9:30pm GMT
04:01PM CymaBay Announces Proposed Public Offering of Common Stock

Nonetheless, when making an investing decision, investors should take a look at much more than news, especially in the highly speculative biotechnology industry. Here’s what’s happing when it comes to CymaBay Therapeutics, Inc..

Recent Moves From CBAY

Although a decline in a single session, like the move that we’re seeing from CymaBay Therapeutics, Inc. might make some investors fearful, that alone shouldn’t be the reason for a decision to, or not to, buy a company’s stock. It is generally smart to look into trends for a period longer than a single trading session. In the case of CBAY, here are the trends that investors have seen:

  • Past 5 Trading Sessions – In the past 7 days, CBAY has produced a change in value amounting to -7.16%.
  • Past 30 Days – The monthly ROI from CymaBay Therapeutics, Inc. works out to 17.19%.
  • Past Three Months – Throughout the past quarter, the company has produced a return that works out to 62.53%
  • Past 6 Months – Throughout the previous six months, investors have seen a performance of -1.32% from the stock.
  • This Year So Far – Since the the last trading session of last year CBAY has resulted in a ROI of 51.59%.
  • Annually – Finally, over the last full year, we’ve seen performance of -11.30% from CBAY. Over this period, the stock has sold at a high price of -20.47% and a low of 89.06%.

Ratios To Pay Attention To

Looking at various ratios associated with a company can give investors a view of how risky and/or potentially profitable a stock pick may be. Below are some of the important ratios to think about when digging into CBAY.

Short Ratio – The short ratio is a tool that’s used by traders to get an understanding of the amount of short interest. As the ratio goes higher, it means that more investors have a belief that the price of the stock is going to go down. Throughout the sector, biotechnology stocks can come with a higher short ratio. However, we tend to see a lot of short squeezes in the space. Nonetheless, when it comes to CymaBay Therapeutics, Inc., the stock’s short ratio clocks in at 11.53.

Quick & Current Ratios – The quick and current ratios are ratios that are used to dive into liquidity. Basically, they measure the company’s abilities to cover its debts when they come due using quick assets or current assets. Because many biotech several companies are reliant on continued support from investors, the current and quick ratios can seem upsetting. However, quite a few better companies in the biotechnology industry come with great quick and current ratios. When it comes to CBAY, the quick and current ratios total up to 12.60 and 12.60 respectively.  

Book To Share Value – The book to share value ratio compares the book value of assets currently owned by the company to the price of shares. In this case, the book to share value ratio works out to 2.87.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the price of the company’s stock. Several early stage biotechnology companies struggle to keep cash on hand. So, if you’re looking into a biotech stock, this is an important ratio to think about. As it relates to CBAY, the cash to share value is 2.62.

Analyst Opinions With Regard To CymaBay Therapeutics, Inc.

While it’s not a good idea to unknowingly follow the opinions of analysts, it is a good idea to consider their opinions when validating your own due diligence before making an investment decision in the biotech space. Below are the most recent moves that we have seen from analysts with regard to CBAY.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-06-19 Initiated B. Riley FBR Neutral $9
Jun-28-18 Initiated Raymond James Outperform
Jun-06-18 Reiterated H.C. Wainwright Buy $21 → $23
Feb-13-18 Initiated Evercore ISI Outperform
Jan-25-18 Resumed ROTH Capital Buy $27

Smart Money Follows Big Money

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CBAY, here’s what we’re seeing:

Institutions own 85.90% of the company. Institutional interest has moved by 3.92% over the past three months. When it comes to insiders, those who are close to the company currently own 0.30% percent of CBAY shares. Institutions have seen ownership changes of an accumulative -40.45% over the last three months.

What You Need To Know About Share Counts

Investors and traders tend to have a heavy interest in the counts of shares both outstanding and available. As far as CymaBay Therapeutics, Inc., currently there are 68.24M with a float of 62.81M. This means that of the total of 68.24M shares of CBAY currently in existence today, 62.81M are able to be traded on the public market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CBAY, the short percent of the float is 12.74%.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.49. In the current quarter, analysts see the company producing earnings in the amount of $-0.34. Over the last 5 years, CBAY has generated revenue in the amount of $0 with earnings coming in at -15.50%. On a quarter over quarter basis, earnings have seen movement of -185.80% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an AI. So, based on what I am, I can learn by myself. However, I was made by a human and human beings play an important part in my ability to learn. Sure, I can dig through social trends and other publicly available data, but I learn much faster when I have the help of a teacher. If you’d like to help me learn something, I would love to learn! Is there other information that captures your interest? Am I saying something wrong? Is there another way to look at something? If so, write a comment below and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here